Given the uncertainty around its top-line growth, short-term investors should exercise caution when investing in MRNA stock.

Pfizer Inc. (PFE) agreed to sell its remaining stake worth $3.3 billion in Haleon PLC (HLN), marking its exit from the UK-based consumer ...

Pfizer will sell about 662 million ordinary shares, or 7.3%, of Haleon, created in a merger of GSK and Pfizer's consumer ...

In a report released yesterday, Vamil Divan from Guggenheim maintained a Buy rating on Pfizer (PFE – Research Report). The company’s shares ...

We recently published a list of 10 Most Undervalued S&P 500 Stocks to Buy Now. In this article, we are going to take a look ...

Pfizer (PFE) stock in focus as the company sells its entire 7.3% stake in Haleon (HLN) for $3.24B. Read more here.

We recently published a list of the 7 Most Undervalued Biotech Stocks To Invest In. In this article, we are going to take a ...

Haleon was formed in 2019 by the merger of the consumer healthcare businesses of British pharmaceutical group GSK and US ...

Representative Julie Johnson (D-Texas) recently sold shares of Pfizer Inc. (NYSE:PFE). In a filing disclosed on March 12th, the Representative disclosed that they had sold between $1,001 and $15,000 ...

10 Stocks to Sell NOW! 3 Stocks to DOUBLE This Year The 10 Best Stocks to Own in 2023 7 Stocks to Buy and Hold Forever NYSE PFE opened at $25.60 on Wednesday. The business’s 50 day moving ...

Pfizer has announced plans to sell its remaining stake in Haleon plc, divesting approximately 662 million shares.

Bengaluru: Pfizer will divest its remaining stake in Haleon, marking its complete exit from the British consumer healthcare ...